Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
I spent the weekend with thousands of blood disease researchers. This is what happened.
Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.